Latest Blog Posts Tagged "Phase II Trial"
December 07, 2018
As we age, the quality of our plasma and its proteins can degrade, which may contribute to problems that damage our brain cells and affect cognition.
October 23, 2018
The Phase II trial is recruiting people with PD ages 40 to 80 to test a drug that targets alpha-synuclein.
January 18, 2018
A Phase II clinical trial to evaluate the safety and tolerability of nilotinib in PD is under way at sites across the US.
February 28, 2017
Jazz Pharmaceuticals recently announced a Phase II trial to test a therapy for excessive daytime sleepiness in people with Parkinson's disease.
February 14, 2017
This study is a major step for PD research as it is the first drug trial where one's genetic information determines eligibility and is testing a potential therapy to slow or stop disease progression.
February 10, 2017
MJFF funded early research of this novel drug candidate, mGluR4, helping remove financial and other barriers to advance its testing.
December 20, 2016
Herantis Pharma was awarded a $6M grant to study the safety and efficacy of a potential therapy for Parkinson's disease (PD): cerebral dopamine neurotrophic factor (CDNF).
September 01, 2016
MJFF-funded trial evaluating a novel therapy to treat Parkinson's disease dementia is actively recruiting.
December 30, 2014
A belt-worn pump that delivers levodopa/carbidopa continuously under the skin may help alleviate the motor fluctuations associated with traditional, oral therapy.
December 23, 2013
The SURE-PD study published in JAMA Neurology reports that with medical supervision, it is possible to safely raise levels of the antioxidant urate by taking the urate precursor inosine.